PubMed Health⌕ Search

Biomedical subjects

David Fox

Publications and source records attributed to David Fox.

6 recordsLinked to original sources
PubMed2006

CD molecules 2006--human cell differentiation molecules.

The Human Leucocyte Differentiation Antigens Workshops (HLDA) have since 1984 provided a forum for the characterization and study of leucocyte surface molecules and antibodies against them. HLDA devised the CD nomenclature, which is sanctioned by IUIS. The HLDA Council reviewed and modified the objectives of HLDA in 2004, and changed the name of the organization to Human Cell Differentiation Molecules (HCDM) to reflect the broader objectives. Workshop studies under the HCDM banner proceeded during 2005 and early 2006, culminating in a meeting in May 2006. At that meeting the Council, acting as Nomenclature Committee, approved a number of new CD designations and changes to some pre-existing CD designations, which are summarized in this report.

Antigens, CD↗
PubMed2006

Development of a murine model of chronic rhinosinusitis.

OBJECTIVE: The aim of this study was to develop a mouse model of chronic eosinophilic rhinosinusitis. STUDY DESIGN: Mice were sensitized to Aspergillis fumigatus (Af) extract by intraperitoneal injection. The animals subsequently received nasal challenges with Af extract 3 times per week for 12 weeks. Sinonasal complexes were studied histologically by the study otolaryngologists and pathologists to characterize the inflammatory response. SETTING: Animal care facility at an academic institution. RESULTS: A chronic eosinophilic inflammatory response was evoked in all study animals. Statistical analysis was performed for inflammation, secretory cell hyperplasia, mast cells, and eosinophils. There were very significant differences (P<0.0005) between control and study mice in all categories. CONCLUSION: Prolonged nasal challenge of Af extract creates an inflammatory response in murine nasal mucosa that mimics human chronic eosinophilic rhinosinusitis. SIGNIFICANCE: A murine model for chronic rhinosinusitis is reported that may facilitate future investigations into disease pathophysiology. EBM RATING: B-2.

Administration, Intranasal↗
PubMed2005

Identification and structural determination of the M(3) muscarinic acetylcholine receptor basolateral sorting signal.

Muscarinic acetylcholine receptors comprise a family of G-protein-coupled receptors that display differential localization in polarized epithelial cells. We identify a seven-residue sequence, Ala(275)-Val(281), in the third intracellular loop of the M(3) muscarinic receptor that mediates dominant, position-independent basolateral targeting in Madin-Darby canine kidney cells. Mutational analyses identify Glu(276), Phe(280), and Val(281) as critical residues within this sorting motif. Phe(280) and Val(281) comprise a novel dihydrophobic sorting signal as mutations of either residue singly or together with leucine do not disrupt basolateral targeting. Conversely, Glu(276) is required and cannot be substituted with alanine or aspartic acid. A 19-amino acid peptide representing the M(3) sorting signal and surrounding sequence was analyzed via two-dimensional nuclear magnetic resonance spectroscopy. Solution structures show that Glu(276) resides in a type IV beta-turn and the dihydrophobic sequence Phe(280)Val(281) adopts either a type I or IV beta-turn.

Alanine↗
PubMed2003

Binding and recognition in the assembly of an active BRCA1/BARD1 ubiquitin-ligase complex.

BRCA1 is a breast and ovarian cancer tumor suppressor protein that associates with BARD1 to form a RINGRING heterodimer. The BRCA1BARD1 RING complex functions as an ubiquitin (Ub) ligase with activity substantially greater than individual BRCA1 or BARD1 subunits. By using NMR spectroscopy and site-directed mutagenesis, we have mapped the binding site on the BRCA1BARD1 heterodimer for the Ub-conjugating enzyme UbcH5c. The results demonstrate that UbcH5c binds only to the BRCA1 RING domain and not the BARD1 RING. The binding interface is formed by the first and second Zn(2+)-loops and central alpha-helix of the BRCA1 RING domain, a region disrupted by cancer-predisposing mutations. Unexpectedly, a second Ub-conjugating enzyme, UbcH7, also interacts with the BRCA1BARD1 complex with similar affinity, although it is not active in Ub-ligase activity assays. Thus, binding alone is not sufficient for BRCA1-dependent Ub-ligase activity.

Amino Acid Sequence↗
PubMed2002

The transposed forearm loop arteriovenous fistula: a valuable option for primary hemodialysis access in diabetic patients.

The distal forearm is the site of first choice for creation of an arteriovenous fistula for hemodialysis. The archetypal procedure, the primary radial-cephalic fistula as described by Brescia, yields excellent functional patency for many patients. Results are much less favorable in patients with diabetes mellitus, for whom non-maturation rates as high as 70% have been reported. This is likely due to inadequate inflow caused by atherosclerotic disease of the forearm arteries in diabetics. Secondary autologous access procedures often involve upper arm configurations such as transposed brachial-basilic fistulas. The present study focuses on a valuable alternative for hemodialysis access in diabetic patients, the transposed forearm loop arteriovenous fistula. Over a 2-year period, 16 forearm loop fistulas were created in 16 diabetic patients who either had a failed radial-cephalic fistula or had arterial anatomy deemed inadequate for wrist fistula formation. In each case, the forearm segment of the basilic or cephalic vein was transposed to form a U-shaped loop and anastomosed to the brachial, proximal radial, or proximal ulnar artery distal to the antecubitai fossa. Functional patency was defined as usability for dialysis. Patency rates were calculated by Kaplan-Meier survival analysis. From our results we determined that the forearm loop fistula is an excellent but underutilized technique that exploits the forearm veins while circumventing the distal arterial supply, thus preserving the upper arm vasculature for future use.

Aged↗